4.1 Kidney Transplantation & Immunosuppression
Key Takeaways
- Comprehensive immunological matching focuses on Class I (HLA-A, HLA-B) and Class II (HLA-DR) alleles to reduce the risk of graft rejection.
- Pre-transplant screening requires complement-dependent cytotoxicity (CDC) or flow cytometry crossmatch testing to detect pre-existing donor-specific antibodies (DSAs).
- Standard maintenance immunosuppression utilizes a triple-drug regimen combining calcineurin inhibitors, antimetabolites, and corticosteroids.
- BK virus screening via plasma PCR is critical for early detection of BK virus-associated nephropathy, which is managed primarily by reducing immunosuppressive therapy.
- Cardiovascular disease remains the leading cause of death in transplant recipients with a functioning graft, driven by accelerated atherosclerosis and immunosuppressant side effects.
Immunological Evaluation and Pre-Transplant Screening
Kidney transplantation is the preferred therapeutic intervention for eligible patients with end-stage kidney disease (ESKD) due to superior long-term survival rates and quality of life compared to maintenance dialysis. A successful outcome requires comprehensive immunological matching to minimize the risk of host-versus-graft reactions.
The primary genetic barrier to transplantation is the Human Leukocyte Antigen (HLA) system, encoded by the major histocompatibility complex (MHC) on chromosome 6. HLA genes are highly polymorphic and are classified into Class I (HLA-A, HLA-B, and HLA-C) and Class II (HLA-DR, HLA-DQ, and HLA-DP). Class I antigens are expressed on all nucleated cells, whereas Class II antigens are expressed on antigen-presenting cells like B-cells and macrophages.
For kidney transplantation, clinical matching focuses on six main alleles: HLA-A, HLA-B, and HLA-DR. A zero-antigen mismatch (6/6 match) provides optimal graft survival, though modern immunosuppressants make HLA mismatches highly manageable. Mismatches are analyzed to calculate rejection risk.
Pre-transplant screening identifies pre-existing antibodies in the recipient against donor HLA, known as donor-specific antibodies (DSAs). Sensitization occurs via pregnancy, blood transfusion, or prior transplant. The calculated Panel Reactive Antibody (cPRA) represents the percentage of donors in a representative donor pool with whom the recipient's antibodies react. High cPRA indicates a highly sensitized candidate who faces longer wait times for a compatible organ.
To prevent hyperacute rejection, physical crossmatch screening is performed before transplant. The complement-dependent cytotoxicity (CDC) crossmatch incubates recipient serum, donor lymphocytes, and complement; cell death indicates cytotoxic antibodies (a positive crossmatch), which is an absolute contraindication.
The more sensitive flow cytometry crossmatch (FCXM) uses fluorescently labeled anti-human IgG antibodies to detect low-trough donor-specific antibodies that may not fix complement but still threaten the graft. Finally, a virtual crossmatch compares recipient antibody profiles, identified via single-antigen bead assays using Luminex technology, with donor HLA typing to predict compatibility.
Graft Rejection: Classifications and Pathophysiology
Graft rejection is classified by timing and pathophysiology:
- Hyperacute rejection occurs within minutes to hours of vascular anastomosis. Pre-existing donor-specific IgG antibodies bind to graft endothelium, activating the complement cascade. This leads to intravascular thrombosis, microvascular congestion, and ischemic necrosis. The process is irreversible and requires immediate graft nephrectomy.
- Acute rejection typically occurs within weeks to months. Acute cellular rejection (ACR) is mediated by T-lymphocytes infiltrating the interstitium and tubules, causing tubulitis. ACR is graded using the Banff classification based on interstitial infiltration (i-score) and tubulitis (t-score) and treated with high-dose intravenous methylprednisolone pulse therapy, or antithymocyte globulin for steroid-resistant cases. Acute antibody-mediated rejection (AMR) is driven by B-lymphocytes producing de novo DSAs against endothelium, histologically characterized by microvascular inflammation (capillaritis), C4d complement degradation product deposition in peritubular capillaries, and glomerulitis. AMR treatment includes plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab.
- Chronic rejection occurs over years, presenting as transplant glomerulopathy, intimal arterial thickening, and interstitial fibrosis and tubular atrophy (IFTA), causing progressive renal decline.
Immunosuppressive Therapies and Clinical Management
Post-transplant regimens include induction and maintenance. Induction therapy is administered perioperatively to prevent immediate rejection. Agents include basiliximab (an interleukin-2 receptor antagonist) for low-risk patients and antithymocyte globulin (a lymphocyte-depleting agent) for high-risk patients.
Maintenance immunosuppression typically utilizes a triple-drug regimen to target multiple T-cell pathways while minimizing toxicity: a calcineurin inhibitor, an antimetabolite, and a corticosteroid.
| Drug Class | Common Agents | Mechanism of Action | Selected Adverse Effects & Nursing Interventions |
|---|---|---|---|
| Calcineurin Inhibitors (CNIs) | Tacrolimus, Cyclosporine | Inhibits calcineurin, preventing interleukin-2 production and T-cell activation. | Nephrotoxicity, neurotoxicity (tremors), hypertension, hyperkalemia, hyperglycemia (tacrolimus), hirsutism and gingival hyperplasia (cyclosporine). Metabolized by CYP3A4; avoid grapefruit juice. Maintain target trough levels. |
| Antimetabolites | Mycophenolate mofetil, Azathioprine | Inhibits purine synthesis, blocking the proliferation of T- and B-lymphocytes. | Leukopenia, thrombocytopenia, anemia, gastrointestinal distress (diarrhea, nausea). Monitor complete blood count (CBC) and handle GI symptoms. |
| Corticosteroids | Prednisone, Methylprednisolone | Broad anti-inflammatory effects; suppresses cytokine gene expression. | Hyperglycemia, osteoporosis, impaired wound healing, mood disturbances, cataracts, Cushingoid features, fluid retention. Educate on calcium intake and blood glucose monitoring. |
Calcineurin inhibitor toxicity presents a clinical paradox: both drug-induced injury and rejection elevate creatinine. Acute CNI toxicity is a functional, reversible vasoconstriction of the afferent arteriole, whereas chronic toxicity leads to irreversible striping fibrosis of the renal parenchyma. Differentiation requires renal biopsy and trough blood level monitoring.
Long-Term Complications of Immunosuppression
Vigilant monitoring is essential to manage complications arising from chronic immunosuppression:
- Viral Infections: BK virus is a major pathogen. Immunosuppression allows this latent polyomavirus to reactivate in the urinary tract, causing BK virus-associated nephropathy (BKVAN), which mimics acute rejection. Biopsy shows intranuclear inclusion bodies in tubular cells. Diagnostic screening utilizes plasma BK PCR. Treatment is a reduction in immunosuppression.
- Malignancies: Recipients have an elevated risk of cancer. Post-transplant lymphoproliferative disorder (PTLD) is a B-cell proliferation strongly associated with Epstein-Barr virus (EBV). Squamous cell skin carcinoma is also highly prevalent, requiring strict sun-safety education.
- Cardiovascular Disease (CVD): CVD is the leading cause of death with a functioning graft. Post-transplant diabetes, hypertension, hyperlipidemia, and CNI metabolic effects accelerate atherosclerosis, requiring statin therapy, blood pressure control, and glycemic monitoring.
A kidney transplant recipient is found to have elevated serum creatinine 3 weeks post-transplant. A renal biopsy shows significant tubulitis, interstitial inflammation, and mononuclear cell infiltration of the tubular epithelium, but is negative for C4d deposition. Which of the following is the most likely diagnosis and appropriate first-line intervention?
Which of the following complications represents the leading cause of death in renal transplant recipients with a functioning graft, and what are the main contributing factors?